• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Kidney failure risk equation (KFRE) discriminates risk in children with chronic kidney disease

byAngela ZhangandAnees Daud
December 29, 2017
in Chronic Disease, Nephrology, Pediatrics, Public Health, Urology
Reading Time: 3 mins read
Meeting families, demographic information affect child abuse work-up
Share on FacebookShare on Twitter

1. The kidney failure risk equation (KFRE), currently used in adults to estimate risk for progression to end-stage renal disease (ESRD) based on demographic and laboratory data, also provides excellent discrimination of ESRD risk in a pediatric cohort with chronic kidney disease.

2. The performance of the KFRE in predicting risk for ESRD in children was similar by race and cause of CKD, but statistically different by ethnicity and age, with improved prediction in Hispanic and older (>12 years old) patients, respectively.

Evidence Rating Level: 2 (Good)

Study Rundown: The kidney failure risk equations (KFREs) is accurate for identifying adults at risk for progression to ESRD, and are currently used to determine timing for dialysis access and kidney transplant. Though previous studies have demonstrated applicability of the KFRE to Canadian, European, and African American cohorts, a similar study had not yet been done to evaluate accuracy of the KFRE in children. Results from this retrospective cohort study demonstrated that both the 4-variable equation (age, sex, eGFR, and ratio of albumin to creatinine levels [ACR]) and 8-variable equation (4-variables plus serum calcium, phosphate, bicarbonate, and albumin levels) provide excellent discrimination of ESRD risk in pediatric participants enrolled in the Chronic Kidney Disease in Children (CKiD) study. The study compared KFRE performance by various patient characteristics, and found no difference in performance based on race (white vs. nonwhite) and cause of CKD (glomerular vs. nonglomerular), but statistically significant differences based on ethnicity (Hispanic vs. non-Hispanic) and age (12+ years vs. >12 years of age).

Limitations of the study included reliance on estimation of albuminuria measurements from proteinuria measurements for a subset of patients, and limited data within subsets of race, ethnicity, and age. Therefore, further study of the influence of these characteristics on the predictive value of KFREs is warranted. Overall, the results of this study have implications for using KFRE to predict ESRD risk in order to improve the timing of anticipatory guidance, referrals of patients to nephrologists, improved completion of immunizations before transplant, and preemptive kidney transplant.

Click to read the study, published in JAMA Pediatrics

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

An intradialytic exercise intervention did not improve dialysis adequacy

Relevant Reading: A predictive model for progression of chronic kidney disease to kidney failure

In-Depth [prospective cohort study]: This study applied the KFRE to a cohort of 603 pediatric participants enrolled in the Chronic Kidney Disease in Children (CKiD) study, who were between the ages of 1 and 16 years and included in the study once their eGFR fell below 60 mL/min/1.73 m2. Their ESRD risks were calculated based on KFRE using 4 variables (age, sex, eGFR, and ratio of albumin to creatinine levels [ACR]) and 8 variables (4 variables plus serum calcium, phosphate, bicarbonate, and albumin levels). Participants were followed prospectively to determine time to ESRD. Overall, both equations were found to provide excellent discrimination of risk, with C-statistics >0.80 for 1-, 2-, and 5-year risks, with a C-statistic of 0.91 for the 8-variable KFRE for 1-year KFRE risk. The performance of the KFRE was similar by race (white vs. nonwhite) and cause of CKD (glomerular vs. nonglomerular), but statistically different by ethnicity (higher in Hispanic vs. non-Hispanic participants, C-statistic difference 0.10; 0.04 to 0.16, 95% CI) and age (higher in participants younger than 12 years vs. 12 years and older, C-statistic difference 0.09; 0.03 to 0.15, 95% CI).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic kidney disease
Previous Post

2 Minute Medicine Rewind December 25, 2017

Next Post

No interventions proven to prevent late-life dementia

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Chronic Disease

An intradialytic exercise intervention did not improve dialysis adequacy

May 18, 2026
FDA-approved weight loss medications associated with weight loss at one year
Chronic Disease

A planetary health diet is associated with a lower risk of developing chronic kidney disease

February 3, 2026
Next Post
Epileptogenic foci may be lateralized using functional brain glutamate imaging

No interventions proven to prevent late-life dementia

Reduced gestational weight gain with lifestyle intervention

Insufficient evidence for physical activity in preventing late-life dementia

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Reduced mortality with culprit-lesion-only percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.